Misonix introduces HIFU prostate cancer treatment to Hungary
21 August 2006
Farmingdale, N.Y., USA. Misonix, Inc. (Nasdaq: MSON)
has formed a strategic relationship with Euro-OPEN KFT for the marketing of
its visually directed high intensity focused ultrasound (HIFU) device for
prostate cancer treatment in Hungary.
Visually Directed HIFU is a new, non-invasive high intensity focused
ultrasound technique developed by Focus Surgery and Misonix and available
only with the Sonablate (SB500). The SB500 is a medical device developed by
Focus Surgery, Inc. and manufactured and distributed in Europe by Misonix.
Misonix's pan-European HIFU strategy now includes access through
in-country and cross border distribution channels into eleven countries in
Europe. In addition to Hungary, these countries include some of the largest
markets in Europe, such as France, Germany, and the United Kingdom. The
United Kingdom is the most advanced market in which Visually Directed HIFU
has been made available, and Misonix says it intends to follow this
successful model in other European countries.
Michael A. McManus, Jr., President and Chief Executive Officer of
Misonix, said, "This expansion into the Hungarian market represents
another integral step to extend Misonix's reach in the European HIFU
market. With a population of 10 million people, Hungarian physicians may
now offer their patients treatment using our proprietary Visually
Directed HIFU on the Sonablate 500."
Dr. Zsolt T. Nemeth, General Manager of Euro-OPEN KFT, said, "We are
very excited about the prospect of delivering the promise of HIFU that
has been proven in other European markets to patients and physicians in